Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2015, Pages

  Hurley, Matthew N ^a,b   Prayle, Andrew P ^c   Flume, Patrick ^d  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZLOCILLIN; AZTREONAM; CARBENICILLIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; OXACILLIN; PIPERACILLIN; SISOMICIN; TICARCILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ALLERGY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BODY MASS; BODY WEIGHT; CYSTIC FIBROSIS; DISEASE EXACERBATION; EFFECT SIZE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG DISEASE; LUNG FUNCTION; MORBIDITY; MORTALITY; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY EXACERBATION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNDERWEIGHT; ADOLESCENT; ADULT; CHILD; DISEASE COURSE; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; TOTAL LUNG CAPACITY;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; HUMANS; INJECTIONS, INTRAVENOUS; TOTAL LUNG CAPACITY;

EID: 84947028649     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009730.pub2     Document Type: Review

References (241)

1. Agostini M, Barlocco G, Bonomi U, Cappelletti LM, Castellani L, Conforti M, et al. Alternative antibiotics against Pseudomonas infections in cystic fibrosis. In vitro activity, pharmacokinetics, and double-blind randomized clinical trial with azlocillin, piperacillin, cefoperazone, ceftazidime, cefsulodin, cefotaxime and moxalactam. Preliminary results. Drugs Under Experimental and Clinical Research 1983;98(9):671-86. [CFGD Register: PI25b]2847370
2. Mastella G, Agostini M, Barlocco G, Bonomi U, Borgo G, Bozzino L, et al. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis. Journal of Antimicrobial Chemotherapy 1983;12(Suppl A):297-311. [CFGD Register: PI25a]2847371
3. Black A, Redmond A, Scott E. Randomised study comparing courses of oral ciprofloxacin alone with intermittent courses of intravenous azlocillin plus tobramycin or oral ciprofloxacin in the treatment of acute exacerbations of respiratory infection in cystic fibrosis [abstract]. 16th Annual Meeting of the European Working Group for Cystic Fibrosis; 1989; Prague, Czechoslovakia. 1989:31. [CFGD Register: PI93a]2847373
4. Black A, Redmond AO, Steen HJ, Oborska IT. Tolerance and safety of ciprofloxacin in paediatric patients. Journal of Antimicrobial Chemotherapy 1990;26(Suppl F):25-9. [CFGD Register: PI93c]2847374
5. Black A, Stevenson M, Scott E, Redmond A. Randomised study comparing oral Ciprofloxacin alone with Ciprofloxacin alternating with intravenous therapy in cystic fibrosis [abstract]. 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen, Denmark. 1991:80. [CFGD Register: PI93b]2847375
6. Blumer JL, Minkwitz M, Saiman L, San Gabriel P, Iaconis J, Melnick D. Meropenem (MEM) compared with ceftazidime (CAZ) in combination with tobramycin (TOB) for treatment of acute pulmonary exacerbations (APE) in patients with cystic fibrosis (CF) infected with Pseudomonas aeruginosa (PA) or burkholderia cepacia (BC) [abstract]. Pediatric Pulmonology 2003;36 Suppl 25:294. [MEDLINE: PI179a]2847377
7. Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005;128:2336-46. [CFGD Register: PI179b; DOI: 10.1378/chest.128.4.2336]2847378
8. Bosso JA, Black PG. A comparative trial of aztreonam and tobramycin plus azlocillin [abstract]. Excerpta Medica, Asia Pacific Congress Series 1988;74:R(c)17. [CFGD Register: PI59a]2847380
9. Bosso JA, Black PG. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatric Infectious Disease Journal 1988;7(3):171-6. [CFGD Register: PI159b]2847381
10. Bosso JA. Use of ciprofloxacin in cystic fibrosis patients. American Journal of Medicine 1989;87(Suppl 5a):123S-7S. [CFGD Register: PI64]2847384
11. Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. American Journal of Medicine 1987;82(4A):180-4. [CFGD Register: PI47]2847383
12. British Thoracic Society Research Committee. Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms. Thorax 1985;40(5):358-63. [CFGD Register: PI37a]2847386
13. Stack BHR, Geddes DM, Williams KJ, Dinwiddie R, Selkon JB, Godfrey RC. Ceftazidime compared with a combination of gentamicin and carbenicillin in cystic fibrosis patients with persistent pulmonary pseudomonas infection and an acute exacerbation of respiratory symptoms [abstract]. 9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England. 1984:4.16. [MEDLINE: PI37b]2847387
14. Caplan DB, Buchanan CN. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. Reviews of Infectious Diseases 1984;6(Suppl 3):S705-10. [CFGD Register: PI32]2847389
15. Church DA, Kanga JF, Kuhn RJ, Rubio TT, Spohn WA, Stevens JC, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Pediatric Infectious Disease Journal 1997;16(1):97-105. [CFGD Register: PI115; MEDLINE: 97155417]2847391
16. Conway SP, Miller MG, Ramsden C, Littlewood JM. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin. Acta Paediatrica Scandinavica 1985;74(1):107-13. [CFGD Register: PI34b]2847393
17. Conway SP, Miller MG, Ramsden CH, Littlewood JM. Comparison of netilmicin-plus ticarcillin and tobramycin plus ticarcillin in exacerbations of pseudomonas chest infection in cystic fibrosis [abstract]. 12th Annual Meeting European Working Group for Cystic Fibrosis; 1983 October; Athens, Greece. 1983:271. [CFGD Register: PI34a]2847394
18. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997;52(11):987-93. [CFGD Register: PI103c; MEDLINE: 98148328]2847396
19. Conway SP, Pond MN, Watson AJ, Robey E, Goldman MH. A safety profile of intravenous colomycin in adult CF care [abstract]. 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:P3. [CFGD Register: PI103a]2847397
20. Conway SP, Pond MN, Watson AJ, Robey H, Goldman MH. Colistin alone or in combination with a second antibiotic is effective in the treatment of respiratory exacerbations in cystic fibrosis [abstract]. Pediatric Pulmonology 1996;22 Suppl 13:296. [CFGD Register: PI103b]2847398
21. Cooper DM, Harris M, Mitchell I. Comparison of intravenous and inhalation antibiotic therapy in acute pulmonary deterioration in cystic fibrosis [abstract]. American Review of Respiratory Disease 1985;131:A242. [CFGD Register: PI129; MEDLINE: 98148328]2847400
22. Costantini D, Padoan R, Brienza A, Lodi G, Assael BM, Giunta A. Clinical evaluation of carbenicillin and sisomicin alone or in combination in CF patients with pulmonary exacerbations [abstract]. 11th European Cystic Fibrosis Conference; 1982; Brussels, Belgium. 1982:227. [CFGD Register: PI122]2847402
23. De Boeck K, Smet M, Eggermont E. Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication. Pediatric Pulmonology 1989;7(3):171-3. [CFGD Register: PI61]2847404
24. De Boeck K, Sauer K, Vandeputte S. Meropenem versus ceftazidime plus tobramycin for pulmonary disease in CF patients [abstract]. The Netherlands Journal of Medicine 1999;54(Suppl):S39. [CFGD Register: PI150; MEDLINE: 98237281]2847406
25. Elborn S, Colville A, Cordon S, Hiller EJ, Shale D. A comparison of intravenous ceftazidime and aztreonam in the treatment of respiratory exacerbations in cystic fibrosis [abstract]. 11th International Cystic Fibrosis Congress; 1992; Dublin, Ireland. 1992:TP17. [CFGD Register: PI97]2847408
26. Gold R, Overmeyer A, Knie B, Fleming PC, Levison H. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatric Infectious Disease 1985;4(2):172-7. [CFGD Register: PI35]2847410
27. Gold R. Mild to moderate chest exacerbations: Do antibiotics help? [abstract]. Pediatric Pulmonology 1987;3:38-9. [CFGD Register: PI67]2847413
28. Gold R, Carpenter S, Heurter H, Corey M, Levison H. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. Journal of Pediatrics 1987;111(6 Pt 1):907-13. [CFGD Register: PI57]2847412
29. Hodson ME, Roberts CM, Butland RJ, Smith MJ, Batten JC. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987;1(8527):235-7. [CFGD Register: PI45c]2847415
30. Hodson ME, Roberts CM, Butland RJA, Batten JC. Ciprofloxacin compared with intravenous azlocillin and gentamicin in the treatment of pseudomonas aeruginosa infection in cystic fibrosis (CF) [abstract]. Pediatric Pulmonology 1987;3:126. [CFGD Register: PI45b]2847416
31. Hodson ME, Roberts CM, Butland RJA, Batten JC. Ciprofloxacin compared with intravenous azlocillin and gentamicin in the treatment of pseudomonas infection in cystic fibrosis (CF) [abstract]. 14th Annual Meeting of the European Working Group for Cystic Fibrosis; 1986 1-2 September; Budapest. 1986:20. [CFGD Register: PI45a]2847417
32. Huang NN, Palmer J, Keith H, Schidlow D, Braverman S, Goldberg M. Comparative efficacy and tolerance study of azlocillin and carbenicillin in patients with cystic fibrosis: a double blind study. Journal of Antimicrobial Chemotherapy 1983;11(Suppl B):205-14. [CFGD Register: PI28]2847419
33. Hyatt AC, Chipps BE, Kumor KM, Mellits ED, Lietman PS, Rosenstein BJ. A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. Journal of Pediatrics 1981;99(2):307-11. [CFGD Register: PI23]2847421
34. Knowles NE, Hallberg TK, Colombe JL. Efficacy of aerosolized antibiotics combined with intravenous treatment of cystic fibrosis pulmonary exacerbation [abstract]. Pediatric Pulmonology 1988;5 Suppl 2:120-1. [CFGD Register: PI87]2847423
35. Macfarlane PI, Hughes DM, Landau LI, Olinsky A. The role of piperacillin therapy in pulmonary exacerbations of cystic fibrosis: a controlled study. Pediatric Pulmonology 1985;1(5):249-55. [CFGD Register: PI39]2847425
36. Master V, Martin AJ, Holmes M, Roberts G, Coulthard K, Kennedy D, et al. Once daily tobramycin monotherapy versus conventional antibiotic therapy for the treatment of pseudomonal pulmonary exacerbations in cystic fibrosis patients [abstract]. European Respiratory Journal 1997;10(Suppl 25):162S. [CFCD Register: PI148a]2847427
37. Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME, et al. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatric Pulmonology 2001;31(5):367-76. [CFGD Register: PI148b]2847428
38. McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, et al. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. Pediatric Pulmonology 1988;4(4):201-4. [CFGD Register: PI58]2847430
39. McLaughlin FJ, Matthews WJ Jr, Strieder DJ, Sullivan B, Goldmann DA. Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis. Journal of Antimicrobial Chemotherapy 1983;11(Suppl B):195-203. [CFGD Register: PI26a]2847432
40. McLaughlin FJ, Matthews WJ Jr, Strieder DJ, Sullivan B, Taneja A, Murphy P, et al. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. Journal of Infectious Diseases 1983;147(3):559-67. [CFGD Register: PI26b]2847433
41. Padoan R, Cambisano W, Costantini D, Crossignani R, Giunta A. Pseudomonas pulmonary infections in cystic fibrosis: Ceftazidime vs ceftazidime plus sisomicin vs piperacillin plus sisomicin [abstract]. 9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England. 1984:Poster 4.21. [CFGD Register: PI52a]2847435
42. Padoan R, Cambisano W, Costantini D, Crossignani RM, Danza ML, Trezzi G, et al. Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. Pediatric Infectious Disease Journal 1987;6(7):648-53. [CFGD Register: PI52b]2847436
43. Penketh AR, Hodson ME, Batten JC. Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosis. British Journal of Diseases of the Chest 1983;77(2):179-84. [CFGD Register: PI27b]2847438
44. Penketh ARL, Hodson ME, Batten JC. Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis [abstract]. 11th European Cystic Fibrosis Conference. 1982:250, Abstract No.: 140. [CFGD Register: PI27c]2847439
45. Penketh ARL, Hodson ME, Batten JC. Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosis [abstract]. Research Conference. 1982:Poster Abstract 3. [CFGD Reference: PI27a]2847440
46. Penketh ARL, Hodson ME, Gaya H, Batten JC. Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis. Thorax 1984;39(4):299-304. [CFGD Register: PI31b]2847443
47. Penketh ARL, Hodson ME, Gaya H, Batten JC. Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis [abstract]. Research Conference. 1982:1. [CFGD Register: PI31a]2847442
48. Regelmann WE, Elliott GR, Clawson CC, Warwick WJ. Reduction of sputum Ps. Aeruginosa density by antibiotics improves lung function in CF more than bronchodilators and chest physiotherapy alone [abstract]. Pediatric Pulmonology 1988;Suppl 2:97. [CFGD Reference: PI65a]2847445
49. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. American Review of Respiratory Disease 1990;141(4 Pt 1):914-21. [CFGD Register: PI65b]2847446
50. Richard DA, Nousia Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. cystic fibrosis Study Group. Pediatric Infectious Disease Journal 1997;16(6):572-8. [CFGD Register: PI127; MEDLINE: 97337367]2847448
51. Salh B, Bilton D, Dodd M, Abbot J, Webb K. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scandinavian Journal of Infectious Diseases 1992;24(2):215-8. [CFGD Register: PI72]2847450
52. Schaad UB, Desgrandchamps D, Kraemer R. Antimicrobial therapy of Pseudomonas pulmonary exacerbations in cystic fibrosis. A prospective evaluation of netilmicin plus azlocillin versus netilmicin plus ticarcillin. Acta Paediatrica Scandinavica 1986;75(1):128-38. [CFGD Register: PI43]2847452
53. Schaad UB, Wedgwood Krucko J, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. Journal of Pediatrics 1987;111(4):599-605. [CFGD Register: PI56]2847454
54. Schaad UB, Wedgwood Krucko J, Guenin K, Buehlmann U, Kraemer R. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. European Journal of Clinical Microbiology & Infectious Diseases 1989;8(10):858-65. [CFGD Register: PI63]2847456
55. Semykin SY, Polikarpova SV, Dubovik LG, Kashirskaya NY. Efficiency of the inhalational tobramycin therapy in complex antibacterial therapy of lung exacerbation in cystic fibrosis children with chronic pseudomonas aeruginosa infection [abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:S55, Abstract no: 214. [CFGD Register: PI246; MEDLINE: 96296083]2847458
56. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, et al. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics 1999;134(4):413-21. [CFGD Register: PI152]2847460
57. Stephens D, Garey N, Isles A, Levison H, Gold R. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatric Infectious Disease 1983;2(3):209-11. [CFGD Register: PI105]2847462
58. Wang CI, Inderlied CB, Armer C, Roldan MA, Osher AB. Comparison of the efficacy and safety of oral ciprofloxacin with that of i.v. tobrarmycin plus azlocillin and/or tobramycin plus ticarcillin in patients with cystic fibrosis [abstract]. Excerpta Medica, Asia Pacific Congress Series 1988;74:R(c)19. [CFGD Register: PI89]2847464
59. Wesley AW, Quested C, Edgar BW, Lennon DR. A double-blind comparison of ceftazidime with tobramycin and ticarcillin in the treatment of exacerbations of pseudomonas chest infection in children with cystic fibrosis [abstract]. Excerpta Medica, Asia Pacific Congress Series 1988;74:R(c)13. [CFGD Register: PI90]2847466
60. Wientzen R, Prestidge CB, Kramer RI, McCracken GH, Nelson JD. Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy. American Journal of Diseases of Children 1980;134(12):1134-8. [CFGD Register: PI22]2847468
61. Aaron S. Clinical evidence for combination antibiotic susceptibility testing (synergy testing) [abstract]. Pediatric Pulmonology 2008;43 Suppl 31:157. [MEDLINE: 96296083]2847471
62. Aaron S, Vandemheen K, Ferris W, Tullis E, Haase D, Berthiaume Y, et al. Treatment of CF exacerbations based on multiple combination antibiotic susceptibility testing-a randomized, double-blind, controlled clinical trial [abstract]. Pediatric Pulmonology 2005;40 Suppl 28:304. [CFGD Register: PI198a]2847470
63. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005;9484(366):463-71. [CFGD Register: PI198b]2847472
64. Adeboyeku D, Jones AL, Hodson ME. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. Journal of Cystic Fibrosis 2011;10(1):25-30. [CFGD Register: PI250; MEDLINE: 96296083]2847474
65. Al Ansari NA, Foweraker J, Mackeown D, Bilton D. Evaluation of once daily tobramycin versus the traditional three times daily for the treatment of acute pulmonary exacerbations in adult cystic fibrosis patients [abstract]. Qatar Medical Journal 2006;15(1):34-8. [CFGD Register: PI173b; MEDLINE: 96296083]2847476
66. Al-Ansari N, McKeon D, Parmer J, Gunn E, Foweraker J, Bilton D. Efficacy of once daily tobramycin for acute pulmonary exacerbations of cystic fibrosis (CF) - a microbiological perspective [abstract]. Thorax 2001;56(Suppl 3):iii85. [CFGD Register: PI173a]2847477
67. Amelina E, Senkevich N, Cherniak A, Cherniaev A, Chuchalin A. Home intravenous therapy in adult cystic fibrosis patients. The impact on lung function and quality of life [abstract]. European Respiratory Journal 2000;16(Suppl 31):123s. [CFGD Register: PI181]2847479
68. Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 2002;50(4):553-9. [CFGD Register: PI158b]2847481
69. Tsang L, Aminimanizani A, Beringer PM, Jelliffe R, Shapiro B. Pharmacokinetics of once-daily tobramycin in adult cystic fibrosis patients [abstract]. Pediatric Pulmonology 2000;30 Suppl 20:284. [CFGD Register: PI158a; MEDLINE: 89332375]2847482
70. Balsamo V, Bragion E, Iapichino L, Natoli D, Pardo F. Clinical efficacy and "in vitro" activity of some antibiotics, ceftazidime aztreonam or carbenicillin with aminoglycosides against pseudomonas in cystic fibrosis patients [abstract]. 14th Annual Meeting of the European Working Group for Cystic Fibrosis; 1986 Sept 1-2; Budapest, Hungary. 1986:63. [CFGD Register: PI84]2847484
71. Beringer P, Shapiro B, Han E, Louie S, Gill M, Rao A. Pharmacodynamics (PD) of continuous infusion (CI) cefepime in adult cystic fibrosis (CF) patients [abstract]. Pediatric Pulmonology 2003;36 Suppl 25:297-8. [CFGD Register: PI178]2847486
72. Beringer P, Owens H, Nguyen A, Benitez D, Boyd-King A, Rao AP. Safety, pharmacokinetics and preliminary evaluation of the antiinflammatory effect of doxycycline in CF. Pediatric Pulmonology 2010;45(Suppl 33):370. 2847488
73. Brett MM, Simmonds EJ, Ghoneim AT, Littlewood JM. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis Comment in: Arch Dis Child 1993 Mar;68(3):432. Archives of Disease in Childhood 1992;67(9):1086-8. [CFGD Register: PI73]2847490
74. Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?. Journal of Antimicrobial Chemotherapy 2006;58(4):822-9. [MEDLINE: PI185b]2847492
75. Lehmann C, Heilmann M, Stichtenoth D, Weissbrodt H, Hohlfeld J. Once-daily versus thrice-daily tobramycin in adult cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology 2004;38 Suppl 27:288. [CFGD Register: PI185a]2847493
76. Byrne S, Maddison J, Connor P, Doughty I, Dodd M, Jenney M, et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 1995;36(Suppl A):135-43. [CFGD Register: PI99b; MEDLINE: 96052005]2847495
77. David TJ, Byrne S, Maddison J, Webb AK, Jenney M, Connor P. Meropenem versus ceftazadime for pseudomonas infection in cystic fibrosis [abstract]. 18th European Cystic Fibrosis Conference; 1993 May 21-26; Madrid, Spain. 1993:PD40. [CFGD Register: PI99a]2847496
78. Cabezudo I, Thompson RL, Selden RF, Guenthner SH, Wenzel RP. Cefsulodin sodium therapy in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 1984;25(1):4-6. [CFGD Register: PI136]2847498
79. Canis F, Trivier D, Vic P, Ategbo S, Turck D, Husson MO. Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis [Comparaison de la pharmacocinetique de la tobramycine administree en dose unique journaliere ou en trois doses dans la mucoviscidose.]. Pathologie-Biologie (Paris) 1998;46(6):449-51. [CFGD Register: PI107c; MEDLINE: 1998442016]2847500
80. Vic P, Ategbo S, Turck D, Husson MO, Launay V, Loeuille GA, et al. Efficacy, tolerance and pharmacokinetics of once-daily (OD) versus thrice-daily (TD) tobramycin (TBM) for pseudomonas aeruginosa (PA) pulmonary exacerbations [abstract]. Pediatric Pulmonology 1996;22 Suppl 13:293. [CFGD Register: PI107a]2847501
81. Vic P, Ategbo S, Turck D, Husson MO, Launay V, Loeuille GA, et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Archives of Disease in Childhood 1998;78(6):536-9. [CFGD Register: PI107b]2847502
82. Christensson BA, Nilsson-Ehle I, Ljungberg B, Lindblad A, Malmborg AS, Hjelte L, et al. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 1992;36(11):2512-7. [CFGD Register: PI119b]2847504
83. Strandvik B, Hjelte L, Lindblad A, Ljungberg B, Malmborg AS, Nilsson Ehle I. Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. Scandinavian Journal of Infectious Diseases 1989;60:84-8. [CFGD Register: PI119a]2847505
84. Conway SP. Ceftazidime 3G BD is as effective as ceftazidime 2G TDS in the treatment of respiratory exacerbations in cystic fibrosis [abstract]. Israel Journal of Medical Sciences 1996; Vol. 32, issue Suppl:S256. [CFGD Register: PI78]2847507
85. Davis RL, Koup JR, Williams Warren J, Weber A, Heggen L, Stempel D, et al. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrobial Agents and Chemotherapy 1987;31(6):915-9. [CFGD Register: PI50]2847509
86. Davis S, Davis P, Mather F, Tankersly P, Waring W. A randomized trial of home intravenous antibiotic therapy (HIVAT) in cystic fibrosis (CF) : Short-term safety and efficacy [abstract]. Pediatric Pulmonology 1990;9 Suppl 5:245. [CFGD Register: PI91a]2847511
87. Davis S, Davis P, Mather F, Waring W, Home IV Antibiotic Study Group. A randomized trial of home intravenous antibiotic therapy (HIVAT) in cystic fibrosis (CF): Short-term psychological effects [abstract]. Pediatric Pulmonology 1990;9 Suppl 5:281-2. [CFGD Register: PI91b]2847512
88. Day AJ, Williams J, McKeown C, Bruton A, Weller PH. Evaluation of inhaled colomycin in children with cystic fibrosis. Excerpta Medica, Asia Pacific Congress Series. 1988:74 R(c)3. 2847514
89. De Boeck K//Breysem L. Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime. Journal of Antimicrobial Chemotherapy 1998;41(3):407-9. [CFGD Register: PI133; MEDLINE: 98237281]2847516
90. Degg C, Mulheran M. The effect of frequent exposure to gentamicin on distortion product OAEs in patients with cystic fibrosis. British Journal of Audiology 1996;30(2):99-100. [CFGD Register: PI167]2847518
91. Dodge J, Zamiri I, Goodchild M, Ingram P. Experience with ceftazidime in cystic fibrosis. J. Antimicrob. Chemother. 1983;12(suppl A):325-329. [DOI: 10.1093/jac/12.suppl_A.325]2847520
92. Donati MA, Guenette G, Auerbach H. Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease. Journal of Pediatrics 1987;111(1):28-33. [CFGD Register: PI143; MEDLINE: 87253633]2847522
93. Elborn JS, Prescott R, Stack B, Shale DJ, Pantin C, Ali N, et al. A comparison of the clinical outcome of symptomatic and elective regular intravenous antibiotics in the treatment of cystic fibrosis [abstract]. Thorax 1997;52(Suppl 6):A4. [CFGD Register: PI155b]2847524
94. Elborn JS, Prescott RJ, Stack BH, Goodchild MC, Bates J, Pantin C, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000;55(5):355-8. [CFGD Register: PI155c]2847526
95. Elborn JS, Prescott RJ, Stack BH, Goodchild MC, Bates J, Pantin C, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs [abstract]. Pediatric Pulmonology 2000;30 Suppl 5:434. [CFGD Register: PI155d]2847525
96. Elborn JS, Prescott RJ, Stack BHR. The British Thoracic Society study of elective versus symptomatic treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis: 5 year results [abstract]. 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:172. [CFGD Register: PI155a]2847527
97. Eron EJ, Park CH, Hixon DL, GoMenberg RI, Poretz DM. Ceftazidime in patients with pseudomonas infectio. J. Antimicrob. Chemother. 1983;12(suppl A):161-169. [DOI: 10.1093/jac/12.suppl_A.161]2847529
98. Gold R, Jin E, Levison H, Isles A, Fleming PC. Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J. Antimicrob. Chemother. 1983;12(suppl A):331-336. [DOI: 10.1093/jac/12.suppl_A.331]2847531
99. Goldfarb J, Stern RC, Reed MD, Yamashita TS, Myers CM, Blumer JL. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. The American Journal of Medicine 1987;82(4A):174-179. [PUBMED: 3555032]2847533
100. Guglielmo BJ, Quan LA, Stulbarg MS. Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients [letter]. Journal of Antimicrobial Chemotherapy 1996;37(5):1040-2. [CFGD Register: PI112; MEDLINE: 96346923]2847535
101. Hamner JR, Poppy A, Ebaugh S, Reiter PD, Pan Z, Wagener J, et al. Pharmacokinetics and safety of once-daily tobramycin in children with cystic fibrosis [abstract]. Pediatric Pulmonlogy 2006;41 Suppl 29:326. [CFGD Register: PI200]2847537
102. Hatziagorou E, Avramidou V, Kirvassilis F, Tsanakas J. Lung clearance index: A tool to assess the response to intravenous treatment among children with cystic fibrosis. Journal of cystic fibrosis 2013;12(Suppl 1):S23. 2847539
103. Heaf DP, Tyson S, Dinwiddie R, Matthew D. A comparison of inhaled therapies in children with cystic fibrosis. 9th International Cystic Fibrosis Congress, June 9th - 15th 1984, Brighton, England. 1984:274. Poster no: 4.08. 2847541
104. Stroobant J, Heaf DP, Tyson S, Matthew DJ. Effect of inhaled azlocillin, mistabron and combination therapy in children with cystic fibrosis. 13th Annual Meeting of the European Working Group for Cystic Fibrosis. 1985:47. 2847542
105. Stroobant J, Heaf DP, Tyson S, Matthew DJ. Effect of inhaled azlocillin, mistabron and combination therapy in children with cystic fibrosis. Pediatric research 1985;19:1099. 2847543
106. Heininger U, Bowing B, Stehr K, Solbach W. Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration [Aminoglykoside bei Patienten mit Mukoviszidose und pulmonaler Exazerbation: Vergleich von Einmal- und Dreimalgabe.]. Klinische Padiatrie 1993;205(1):18-22. [CFGD Register: PI74]2847545
107. Hjelte L, Widen B, Malmborg AS, Freyschuss U, Strandvik B. Intravenous administration of antibiotics at home in patients with cystic fibrosis improves quality of life. Lakartidningen 1988;85(18):1614-7. 2847547
108. Hoogkamp-Korstanje JA, van der Laag J. Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis. Journal of Antimicrobial Chemotherapy 1983;12(2):175-83. [CFGD Register: PI140; MEDLINE: 84007879]2847549
109. Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrobial Agents and Chemotherapy 2009;53(9):3650-6. [CFGD Register: PI180b; MEDLINE: 96296083]2847551
110. Hubert D, Wallaert B, Scheid P, Ramel S, Grenet D, Sermet-Gaudelus I, et al. Continuous infusion versus intermittent administration of ceftazidime in cystic fibrosis patients [abstract]. Pediatric Pulmonology 2003;36 Suppl 25:294. [CFGD Register: PI180a]2847552
111. Ivanov V, Shabalova L, Holmes C, Hill C, Illangovan P, O'Hara S, et al. Ceftazidime bid vs tid in the treatment of bacterial respiratory exacerbations in Russian cystic fibrosis [abstract]. Pediatric Pulmonology 1997;25 Suppl 14:292. [CFGD Register: PI125]2847554
112. Jackson MA, Kusmiesz H, Shelton S, Prestidge C, Kramer RI, Nelson JD. Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis. Pediatric Infectious Disease 1986;5(4):440-3. [CFGD Register: PI38b]2847556
113. Nelson JD. Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal. Journal of Pediatrics 1985;106(6):1030-4. [CFGD Register: PI38a]2847557
114. Jacobs RF, Trang JM, Kearns GL, Warren RH, Brown AL, Underwood FL, et al. Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis. Journal of Pediatrics (ST LOUIS) 1985;106(6):1001-7. [CFGD Register: PI142]2847559
115. Jensen T, Pedersen SS, Hoiby N, Koch C. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. European Journal of Clinical Microbiology 1987;6(6):618-22. [CFGD Register: PI55c]2847561
116. Jensen T, Pedersen SS, Nielsen CH, Hoiby N, Koch C. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy 1987;20(4):585-94. [CFGD Register: PI55a]2847562
117. Pedersen SS, Jensen T, Hvidberg EF. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 1987;20(4):575-83. [CFGD Register: PI155b]2847563
118. Jewett CV, Ledbetter J, Lyrene RK, Brasfield DM, Tiller RE. Comparison of cefoperazone sodium vs methicillin, ticarcillin, and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis. Journal of Pediatrics 1985;106(4):669-72. [CFGD Register: PI36]2847565
119. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, et al. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrobial agents and chemotherapy 2011;55(7):3393-8. 2847567
120. Kercsmar CM, Stern RC, Reed MD, Myers CM, Murdell D, Blumer JL. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. Journal of Antimicrobial Chemotherapy 1983;12(Suppl A):289-95. [DOI: 10.1093/jac/12.suppl_A.289]2847569
121. Klettke U, Magdorf K, Staab D, Bisson S, Paul K, Wahn U. Ambulatory vs. inpatient intravenous antibiotic therapy in mucoviscidosis patients--a controlled study [Ambulante vs. stationare intravenose antibiotische Therapie bei Mukoviszidosepatienten--Eine kontrollierte Studie]. Pneumologie 1999;53(1):31-6. [CFGD Register: PI108b]2847571
122. Klettke U, Magdorf K, Staab D, Paul K, Wahn U. Can home therapy replace hospital intravenous antibiotic therapy in patients with cystic fibrosis in Germany? [abstract]. Pediatric Pulmonology 1996;22 Suppl 13:340. [CFGD Register: PI108a]2847572
123. Magdorf K, Klettke U, Staab D, Paul K, Wahn U. Home intravenous antibiotic therapy vs. hospital therapy - an alternative for patients with cystic fibrosis? [abstract]. Monatsschrift fur Kinderheilkunde 1996;144:1047. [CFGD Register: PI108d]2847573
124. von der Schulenburg JM, Greiner W, Klettke U, Wahn U. Economic aspects in treatment of cystic fibrosis with chronic pulmonary pseudomonas infection. Ambulatory intravenous therapy in comparison with inpatient treatment [Okonomische Aspekte der Behandlung zystischer Fibrose mit chronischer pulmonaler Pseudomonasinfektion. Ambulante intravenose Therapie im Vergleich zur stationaren Behandlung]. Medizinische Klinik 1997;92(10):626-9. [CFGD Register: PI108c]2847574
125. Krause PJ, Young LS, Cherry JD, Osher AB, Spencer MJ, Bryson YJ. The treatment of exacerbations of pulmonary disease in cystic fibrosis: netilmicin compared with netilmicin and carbenicillin. Current Therapeutic Research, Clinical and Experimental 1979;25:609-17. [CFGD Register: PI166]2847576
126. Junge S, Kruger K, Schonweiler R, Ptok M, Ballmann M. Once daily dosage of intravenous tobramycin - increased risk for cochlea damage in children with cystic fibrosis (CF)? [abstract]. Pediatric Pulmonology 2001;32 Suppl 22:291. [CFGD Register: PI160b]2847578
127. Kruger K, Junge S, Schonweiler R, Ptok M, Ballmann M. Once daily dosage of intravenous tobramycin in patients with cystic fibrosis - increased risk for cochlea damage? [abstract]. 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P191. [CFGD Register: PI160a]2847579
128. Kuni CC, Regelmann WE, duCret RP, Boudreau RJ, Budd JR. Aerosol scintigraphy in the assessment of therapy for cystic fibrosis. Clinical Nuclear Medicine 1992;17(2):90-3. [CFGD Register: PI236]2847581
129. Kuzemko J, Crawford C. Continuous infusion of ceftazidime in cystic fibrosis [letter]. Lancet 1989;2(8659):385. [CFGD Register: PI16; MEDLINE: 89343367]2847583
130. Labiris R, Freitag A, Pratt B, Efthimiadis A, Hargreave F, Dolovich M. Does inhalation of preservatives from IV tobramycin preparations (TOB) cause airway inflammation? [abstract]. American Journal of Respiratory and Critical Care Medicine 2004;169(7):A307. [CFGD Register: PI182]2847585
131. Levy J, Baran D, Klastersky J. Anti-pseudomonas activity of azlocillin during pulmonary infection in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 1982;10(3):235-8. [CFGD Register: PI141; MEDLINE: 83056612]2847587
132. Levy J, Baran D, Klastersky J. Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 1982;10(3):227-34. [CFGD Register: PI134; MEDLINE: 83056611]2847589
133. Bowes G, Li SC, Williams TJ, Spicer WJ, McLean AJ. Computer-aided tobramycin in adults with cystic fibrosis [abstract]. Pediatric Pulmonology 1988;Suppl 2:92. [CFGD Register: PI71a]2847591
134. Li SC, Bowes G, Ioannides Demos LL, Spicer WJ, Hooper RE, et al. Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 1991;28(4):561-8. [CFGD Register: PI71b]2847592
135. Martin AJ, Smalley CA, George RH, Gealing DE, Anderson CM. Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis. Archives of Disease in Childhood 1980;55:604-7. [CFGD Register: PI20]2847594
136. McCabe D, Rodgers HC. Evaluation of a twice daily tobramycin regimen in adult cystic fibrosis patients. Journal of cystic fibrosis 2013;12(Suppl 1):S71. 2847596
137. Michalsen H, Bergan T. Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis. Scandinavian Journal of Infectious Disease. Supplementum 1981;29:92-97. 2847598
138. Moss RB. Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. Journal of Allergy and Clinical Immunology 1991;87(1 Pt 1):78-88. [CFGD Register: PI163]2847600
139. Mouton JW, Horrevorts AM, Overbeek S, Kerrebijn KF, Michel MF. Pharmacokinetics of Ceftazidime during continuous and intermittent infusion in cystic fibrosis patients [abstract]. 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen, Denmark. 1991:88. [CFGD Register: PI96]2847602
140. Nikolaizik WH, Vietzke D, Ratjen F. A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients. Canadian Respiratory Journal 2008;15(5):259-62. [CFGD Register: PI191c]2847604
141. Nikolaizik WH, Vietzke D, Ratjen F. Comparison of tobramycin 80 mg (IV- Preparation) and 300mg solution for inhalation in cystic fibrosis patients [abstract]. European Respiratory Journal 2005;26(Suppl 49):620s. [CFGD Register: PI191b]2847605
142. Nikolaizik WH, Vietzke D, Ratjen F. Comparison of tobramycin 80mg (IV-preparation) and 300mg solution inhaled twice daily for chronic P. aeruginosa infection [abstract]. Journal of Cystic Fibrosis 2005;4 Suppl:S53. [CFGD Register: PI191a]2847606
143. Nikonova VS, Kashirskaya NY, Kapranov NI. Efficacy and safety of tobramycin and colistin for inhalation in children with cystic fibrosis from Moscow region. Journal of cystic fibrosis 2010;9(Suppl 1):S54. 2847608
144. Padoan R, Costantini D, Crossignani RM, Colavita G, Cambisano W, Cesana B, et al. Ceftazidime once a day vs t.i.d. in pseudomonas lung infection in cystic fibrosis patients [abstract]. Excerpta Medica, Asia Pacific Congress Series 1988;74:R(c)12. [CFGD Register: PI88]2847610
145. Parry MF, Neu HC, Merlino M, Gaerlan PF, Ores CN, Denning CR. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. Journal of Pediatrics 1977;90(1):144-8. [CFGD Register: PI17]2847612
146. Pedersen SS, Pressler T, Pedersen M, Hoiby N, Friis Moller A, Koch C. Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. Scandinavian Journal of Infectious Diseases 1986;18(2):133-7. [CFGD Register: PI42]2847614
147. Permin H, Koch C, Hoiby N, Christensen HO, Moller AF, Moller S. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy 1983;12(Suppl A):313-23. [CFGD Register: PI29]2847616
148. Popa I, Pop L, Moldoban R, Popa Z, Liker M, Popa ZL. The comparative efficiency of ceftazidime and meropenem within the pseudomonas aeruginosa infection in cystic fibrosis [abstract]. 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P207. [CFGD Register: PI161]2847618
149. Postnikov SS, Semykin SJ, Najimov VP. Safety of fluoroquinolones in children [abstract]. 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P213. [CFGD Register: PI162]2847620
150. Postnikov SS, Semiakin SI, Nazhimov VP, Kapranov NI. Comparative yearly growth rate of children with mucoviscidosis treated and not treated with ciprofloxacin:clinicomorphological comparisons [Cravnitel'naiia godovaia skorost' rosta u detei s mukovistsidozom, poluchavshikh i nepolychavshikh tsiprofloksatsin:klinicomorfologicheskie copostavleniia.]. Antibiotiki I Khimioterapiia 2001;46(10):11-3. [CFGD Register: PI169]2847622
151. Postnikov SS, Semykin SY, Polikarpova SV, Dubovik LG, Gracheva LA, Sagatelyan RM. A prospective trial on the efficacy and tolerability of twice-daily dosing (TDD) versus once-daily dosing (ODD) amikacin in cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2007;6 Suppl 1:S34. [CFGD Register: PI204]2847624
152. Powell SH, Stern RC, Thompson WL. Safety of once daily therapy with high-dose tobramycin [abstract]. 20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 May 1; Atlanta, Georgia. 1979:74. [CFGD Register: PI139b]2847626
153. Powell SH, Thompson WL, Luthe MA, Stern RC, Grossniklaus DA, Bloxham DD, et al. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. Journal of Infectious Diseases 1983;147(5):918-32. [CFGD Register: PI139a; MEDLINE: 83187728]2847627
154. Prayle A, Jain K, Watson A, Smyth AR. Are morning doses of intravenous tobramycin less nephrotoxic than evening? Evidence from urinary biomarkers in the critic study. Pediatric Pulmonology 2013;48(Suppl 36):299. 2847629
155. Ramstrom H, Erwander I, Mared L, Kornfalt R, Seiving B. Pharmaceutical intervention in the care of cystic fibrosis patients. Journal of Clinical Pharmacy and Therapeutics 2000;25(6):427-34. [CFGD Register: PI159]2847631
156. Reed MD, Stern RC, Myers CM, Klinger JD, Yamashita TS, Blumer JL. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology 1987;3(2):101-9. [CFGD Register: PI46]2847633
157. Reed MD, Stern RC, O'Brien CA, Crenshaw DA, Blumer JL. Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 1987;31(5):698-702. [CFGD Register: PI49]2847635
158. Riethmueller J, Ballmann M, Schroeter TW, Franke P, von Butler R, Claass A, et al. Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection 2009;37(5):424-31. [CFGD Register: PI154f; MEDLINE: 96296083]2847637
159. Riethmueller J, Busch A, Franke P, Ziebach R, von Butler R, Stern M. Pharmacodynamic variation of intravenous antibiotic treatment with ceftazidime and tobramycin in CF-patients is equally effective [abstract]. 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:166. [CFGD Register: PI154a]2847638
160. Riethmueller J, Franke P, Schroeter TW, Claass A, Busch A, Ziebach R, et al. Optimised intravenous antibiotic treatment with ceftazidime (thrice daily vs continuous) and tobramycin (thrice vs once daily) in CF patients [abstract]. 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P192. [CFGD Register: PI154b]2847639
161. Riethmueller J, Junge S, Schroeter TW, Kuemmerer K, Franke P, Ballmann M, et al. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009;37(5):418-23. [CFGD Register: PI154e; MEDLINE: 96296083]2847640
162. Schroeter T, Eggert P, Riethmueller J, Stern M, Claass A. Acute-phase nephrotoxicity of tobramycin in CF patients: A prospective randomized trial of once-versus thrice-daily dosing [abstract]. Pediatric Pulmonology 2002;34 Suppl 24:289. [CFGD Register: PI154d]2847641
163. Schroeter TW, Eggert P, Riethmueller J, Stern M, Claass A. A prospective randomized trial on the nephrotoxicity of thrice-daily versus once-daily tobramycin in cystic fibrosis patients [abstract]. 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P190. [CFGD Register: PI154c]2847642
164. Roberts GW, Nation RL, Jarvinen AO. Measurement of serum tobramycin in the presence of ticarcillin or piperacillin. Australian Journal of Hospital Pharmacy 1992;22(2):152-4. [CFGD Register: PI132b]2847645
165. Roberts GW, Nation RL, Jarvinen AO, Martin AJ. An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients. British Journal of Clinical Pharmacology 1993;36(4):372-5. [CFGD Register: PI134a]2847644
166. Rubio TT. Ciprofloxacin: comparative data in cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4A):185-8. [CFGD Register: PI137; MEDLINE: 87210209]2847647
167. Shatunov SM. Comparative efficacy of different methods of ceftazidime administration in children with cystic fibrosis [abstract]. 11th European Respiratory Society Annual Congress; 2001 Sept 22-26; Berlin. 2001:860. [CFGD Register: PI164]2847649
168. Mulheran M, Hyman-Taylor P, Tan KH, Lewis S, Stableforth D, Knox A, et al. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 2006;50(7):2293-9. [CFGD Register: PI172e]2847651
169. Smyth A, Doherty C, Govan J, Tan K, Hyman-Taylor P, Stableforth D, et al. Once daily tobramycin achieves cidal levels against Pseudomonas Aeruginosa in patients with cystic fibrosis [abstract]. Thorax 2001;56(Suppl 3):iii84. [CFGD Register: PI172a]2847652
170. Smyth A, Tan K, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al. A randomised controlled trial of once vs three times daily tobramycin for pulmonary exacerbations of cystic fibrosis (the TOPIC study) [abstract]. Pediatric Pulmonology 2003;36 Suppl 25:292. [CFGD Register: PI172b]2847653
171. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial. Lancet 2005;365(9459):573-8. [CFGD Register: PI172c]2847654
172. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics (PK) of tobramycin administered thrice daily (TD) and once daily (OD) in children and adults with CF [abstract]. Journal of Cystic Fibrosis 2007;6 Suppl 1:S16. [CFGD Register: PI172f]2847655
173. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. Journal of Cystic Fibrosis 2007;6(5):327-33. [CFGD Register: PI172g]2847656
174. Vandenbussche HL, Klepser ME. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs? [comment]. Lancet 2005;365(9459):547-8. [CFGD Register: PI172d]2847657
175. Turner R, Biondo LR, Slain D, Phillips U, Cardenas SC, Moffett K. A randomized pilot study of continuous versus intermittent infusion piperacillin-tazobactam for the treatment of pulmonary exacerbations in patients with cystic fibrosis. Pediatric pulmonology 2013;48(Suppl 36):326. 2847659
176. Byrnes CA, Vidmar S, Cheney JL, Carlin JB, Armstrong DS, Cooper PJ, et al. Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. Thorax 2013;68(7):643-51. 2847661
177. Cheney J, Vidmar S, Grimwood K, Carlin JB, Wainwright C, on behalf of ACFBAL Study Group. Interim outcomes of a Pseudomonas aeruginosa (Pa) eradication protocol in young children in the Australian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) Study [abstract]. Journal of Cystic Fibrosis 2009;8(Suppl 2):S39, Abstract no:157. [CFGD Register: PE167c]2847662
178. Cheney J, Wainwright C, ACFBAL Study Group. Trials, tribulations and triumphs of a cystic fibrosis study - a behind the scenes look at the workings of an international multi-centre study [abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:S118, Abstract no: 452. [CFGD Register: PE167g; ]2847663
179. Wainwright C, Carlin J, Cooper P, Byrnes C, Martin J, Grimwood K, et al. Australasian cystic fibrosis BAL study interim analysis [abstract]. Pediatric Pulmonology 2006;41 Suppl 29:317. [CFGD Register: PE167a]2847664
180. Wainwright CE, Carlin J, Cooper P, Byrnes C, Whitehead B, Martin J, et al. Early infection with pseudomonas aeruginosa can be cleared in young children with cystic fibrosis [abstract]. Pediatric Pulmonology 2002;34 Suppl 24:300-1. [CFGD Register: PI167d]2847666
181. Wainwright CE, Kidd TJ, Ramsey KA, Bell SC, Grimwood K. Australasian CF bronchoalveolar lavage (ACFBAL) study: P.Aeruginosa (PA) genotypes in pre-school CF children [abstract]. Pediatric Pulmonology 2011;46 Suppl 34:320, Abstract no: 299. [CFGD Register: PE167h; ]2847667
182. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011;306(2):163-71. [CFGD Register: PE167e]2847668
183. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, et al. Online Supplement to 'Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial' [online]. JAMA 2011;306(2):163-171 Online. [CFGD Register: PE167f; ]2847669
184. Wainwright CE, Grimwood K, Carlin JB, Vidmar S, Cooper PJ, Francis PW, et al. Safetyofbronchoalveolar lavageinyoung childrenwith cystic fibrosis. Pediatric Pulmonology 2008;43(10):965-72. [CFGD Register: PE167b]2847665
185. Watson A, Whitehead A, Conway SP, Etherington C. Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients [abstract]. Pediatric Pulmonology 1999;28 Suppl 19:262-3. [CFGD Register: PI149b]2847671
186. Whitehead A, Conway SP Etherington C, Dave J. Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients [abstract]. The Netherlands Journal of Medicine 1999;54(Suppl):S36-7. [CFGD Register: PI149a]2847672
187. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. European Respiratory Journal 2002;19(2):303-9. [CFGD Register: PI149c]2847673
188. Winnie GB, Cooper JA, Witson J, Cowan RG, Mayer D, Lepow M. Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients. Pediatric Infectious Disease Journal 1991;10(5):381-6. [CFGD Register: PI69]2847675
189. Wolter JM, Bowler SD, McCormack JG, Nolan PJ. Home versus hospital therapy including intravenous antibiotics in cystic fibrosis [abstract]. 11th Annual Scientific Meeting of the Thoracic Society of Australia and New Zealand (TSANZ). 1994:148. [CFGD Register: PI130a]2847677
190. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. European Respiratory Journal 1997;10(4):896-900. [CFGD Register: PI130b; MEDLINE: 97294575]2847678
191. Wood PJ, Ioannides Demos LL, Li SC, Williams TJ, Hickey B, Spicer WJ, et al. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996;51(4):369-73. [CFGD Register: PI109; MEDLINE: 96296083]2847680
192. Yasmin N, Laraya-Cuasay LR, Mueller S, Liberi P, Braverman S, Capitanio M, et al. A critical evaluation of antibiotic aerosol in patients with cystic fibrosis [abstract]. 15th Annual Meeting Cystic Fibrosis Club Abstracts; 1974. 1974. [CFGD Register: PI79]2847682
193. Al-Aloul M, Miller H, Browning P, Ledson MJ, Walshaw MJ. A randomised cross over trial of TOBI® vs IV tobramycin in acute pulmonary exacerbations in CF [abstract]. Pediatric Pulmonology 2004;38 Suppl 27:249. [CFGD Register: PI186a]2847684
194. Al-Aloul M, Miller H, Ledson MJ, Walshaw MJ. Tobramycin nebuliser solution in the treatment of cystic fibrosis pulmonary exacerbations: effect on sputum pseudomonas aeruginosa density [abstract]. Thorax 2005;2(Suppl 2):ii92. [CFGD Register: PI186b; MEDLINE: 96296083]2847685
195. Beaudry PH, Marks MI, McDougall D, Desmond K, Rangel R. Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?. Journal of Pediatrics 1980;97(1):144-7. [CFGD Register: PI121a]2847687
196. Beaudry PH, Marks MI, Rangel R, McDougall D, Desmond K. Is anti-pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? [abstract]. 20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 may 1; Atlanta, Georgia, USA. 1979 May:1. [CFGD Register: PI121b]2847688
197. Crawley J, Ledson MJ, Walshaw MJ. Use of subcutaneous antibiotics to treat pseudomonas infection in an adult CF centre [abstract]. Journal of Cystic Fibrosis 2005;4 Suppl 1:S52. [CFGD Register: PI94]2847690
198. Dinwiddie R, Hindmarsh P, Lock P. Azlocillin compared to gentamicin in the treatment of pseudomonas infection in cystic fibrosis [abstract]. 11th European Cystic Fibrosis Conference; 1982; Brussels, Belgium. 1982:229. [CFGD Register: PI123]2847692
199. Döring G, Stiller T, Magdorf K, Wahn U. Impact of antibiotic therapy on neutrophil elastase release in cystic fibrosis patients [abstract]. American Journal of Respiratory and Critical Care Medicine 1995;151(4):A248. [CFGD Register: PI60; MEDLINE: 87253633]2847694
200. Geborek A, Hjelte L, Lindblad A, Mared L, Eriksson L, Johannesson M, et al. Cross-over study of TOBI® vs. intravenous tobramycin in combination treatment of pulmonary exacerbations in cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2003;2 Suppl 1:S22. [CFGD Register: PI176]2847696
201. Harris M, Cooper DM, Mitchell I. Exercise testing in assessing therapy for respiratory infections [abstract]. Proceedings of the 9th International Cystic Fibrosis Congress, Brighton, England 1984;-:240. 2847698
202. Huang N, Palmer J, Schidlow D, Hsuan F, Hsu C, Goldberg M, et al. Evaluation of antibiotic therapy in patients with cystic fibrosis [abstract]. Chest 1979;76(3):354-5. [CFGD Register: PI113]2847700
203. Huang NN, Palmer J, Braverman S, Keith HH, Schidlow D. Therapeutic efficacy of ticarcillin and carbenicillin in patients with cystic fibrosis: a double blind study [abstract]. 23rd Annual Meeting Cystic Fibrosis club abstracts; 1982 May 14; Washington D.C, USA. 1982:124. [CFGD Register: PI114]2847701
204. Kapranov NI, Belousov YB, Kashyrskaya NY, Smirnova EY. Quinoline therapy in children with cystic fibrosis [abstract]. 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:P19. [CFGD Register: PI104]2847703
205. Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. Journal of Cystic Fibrosis 2008;7(2):142-6. [CFGD Register: PI209; MEDLINE: 96296083]2847705
206. Parry MF, Neu HC. A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to gram-negative bacilli. American Journal of Medicine 1978;64(6):961-6. [CFGD Register: PI18]2847707
207. Vic P, Ategbo S, Gottrand F, Launay V, Loeuille GA, Elian JC, et al. Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis. Archives of Disease in Childhood 1997;76(5):437-40. [CFGD Register: PI126; MEDLINE: 97339807]2847709
208. Ballmann M, Rabsch P, von der Hardt H. Long term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 1998;53(9):732-7.
209. Bertenshaw C, Watson A, Lewis S, Smyth A. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2007;62(6):541-5.
210. Bilton D, Canny G, Conway S, Dumcius S, Hjelte L, Proesmans M, et al. Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. Journal of Cystic Fibrosis 2011;10(Suppl 2):S79-81.
211. Blainey PC, Milla CE, Cornfield DN, Quake SR. Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis. Science Translational Medicine 2012;4(153):153ra130. [DOI: 10.1126/scitranslmed.3004458]
212. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121(2):64-72. [DOI: 10.1378/chest.121.1.64]
213. Brody AS, Sucharew H, Campbell JD, Millard SP, Molina PL, Klein JS, et al. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2005;172(9):1128-32. [DOI: 10.1164/rccm.200407-989OC]
214. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2010. www.cff.org/LivingWithCF/CareCenterNetwork/PatientRegistry/ (accessed 06 February 2011).
215. de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011;66(8):680-5. [DOI: 10.1136/thx.2011.161117]
216. Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
217. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. European Respiratory Journal 2000;16(4):749-67. [PUBMED: 11106223]
218. Elphick HE, Jahnke N. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD002007.pub3]
219. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. American Journal of Respiratory and Critical Care Medicine 2009;180(9):802-8. [DOI: 10.1164/rccm.200812-1845PP]
220. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New England Journal of Medicine 1994;331(10):637-42. [DOI: 10.1056/NEJM199409083311003]
221. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003;167(6):841-9.
222. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007;62(4):360-7. [DOI: 10.1136/thx.2006.060889]
223. Guss AM, Roeselers G, Newton ILG, Young CR, Klepac-Ceraj V, Lory S, et al. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. International Society for Microbial Ecology Journal 2011;5(1):20-9.
224. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
225. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
226. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
227. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD004197.pub3]
228. Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD006682.pub4]
229. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
230. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358(9286):983-4.
231. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
232. Rogues AM, Dumartin C, Amadéo B, Venier AG, Marty N, Parneix P. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infection Control and Hospital Epidemiology 2007;28(12):1389-95. [DOI: 10.1086/523280]
233. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: A consensus statement. Journal of Pediatrics 1998;132(4):589-95. [DOI: 10.1016/S0022-3476(98)70344-0]
234. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. American Journal of Respiratory and Critical Care Medicine 2010;182(5):627-32.
235. Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. American Journal of Respiratory and Critical Care Medicine 2006;174(7):780-6. [DOI: 10.1164/rccm.200512-1919OC]
236. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD002009.pub5]
237. Sterne J, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
238. Stressmann FA, Rogers GB, March P, Lilley AK, Daniels TW, Carroll MP, et al. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?. Journal of Cystic Fibrosis 2011;10(5):357-65. [ISSN: 1569-1993]
239. Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP, et al. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax 2012;67(10):867-73. [DOI: 10.1136/thoraxjnl-2011-200932]
240. Wagener JS, Rasouliyan L, Van Devanter DR, Pasta DJ, Regelmann WE, Morgan WJ, et al. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology 2013;48:666-73. [DOI: 10.1002/ppul.22652]
241. Creative Consulting for Research and Education. XYPLOT. Creative Consulting for Research and Education, 2010. [CCREweb.org]